Intelligent Bio Solutions Initiates FDA 510(k) Pharmacokinetic Study with Successful Recruitment and Subject Screening
NEW YORK, May 29, 2024 - Intelligent Bio Solutions Inc. (Nasdaq: INBS), a pioneering medical technology company renowned for its intelligent, rapid, and non-invasive testing solutions, proudly announces the accomplishment of successful recruitment and the initiation of subject screening for its crucial pharmacokinetic (PK) study. This study plays a pivotal role in the Company’s efforts to obtain FDA 510(k) regulatory clearance.
Intelligent Bio Solutions has long been at the forefront of groundbreaking innovations, dedicated to transforming the healthcare landscape. By continuously pushing the boundaries of technology, the Company has consistently developed and delivered cutting-edge solutions for accurate and efficient medical testing.
Through extensive research and development, Intelligent Bio Solutions has harnessed the power of artificial intelligence and rapid testing methodologies to create non-invasive testing solutions that significantly enhance patient experience and improve overall healthcare outcomes. This commitment to innovation has led to the successful recruitment of subjects for its crucial PK study, marking a significant milestone in the regulatory journey of the Company.
The pharmacokinetic study is a vital component of securing FDA 510(k) clearance. Pharmacokinetics is the study of how a drug is absorbed, distributed, metabolized, and eliminated within the body. By examining the drug’s behavior and its interaction with the body, this study provides valuable insights into the drug’s efficacy and safety profile.
Intelligent Bio Solutions’ steadfast focus on conducting this PK study reinforces its dedication to meeting the highest regulatory standards. The Company believes that by comprehensively evaluating the pharmacokinetics of their innovative testing solutions, they can contribute to the advancement of healthcare by delivering accurate, reliable, and non-invasive diagnostic tools that can revolutionize patient care.
We are thrilled to have reached this pivotal moment in our journey towards FDA regulatory clearance. The successful recruitment and commencement of subject screening for our PK study exemplify our commitment to delivering next-generation medical technologies, said Dr. Amanda Robertson, CEO of Intelligent Bio Solutions. By conducting rigorous studies that assess the pharmacokinetics of our solutions, we aim to not only meet regulatory requirements but also pave the way for a new era of intelligent and patient-centered healthcare.
With subject screening now underway, Intelligent Bio Solutions is positioned to gather significant data that will further strengthen the scientific foundation of its innovative testing solutions. The Company’s relentless pursuit of excellence ensures that its technologies continue to empower healthcare professionals with accurate and timely information, ultimately fostering better clinical decision-making and improving patient outcomes.
In conclusion, Intelligent Bio Solutions’ achievement in successfully recruiting subjects and commencing subject screening for its pivotal pharmacokinetic study demonstrates the Company’s unwavering commitment to delivering advanced medical technologies that revolutionize healthcare. The initiation of this study brings them closer to achieving FDA 510(k) regulatory clearance, bolstering their reputation as a leader in the field of non-invasive testing solutions.
Comments